News Room

A new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA) and Deloitte Center for Health Solutions outlines five critical strategies for enhancing diversity in clinical trials during the research and development of new medicines.

Patients with serious chronic diseases report major challenges in getting the right medication because of insurance practices that force them to fail on less expensive medications first, and minority populations suffer disproportionately, according a new survey by PhRMA examining barriers people face in accessing health care and prescription medicines.

A new Ipsos/PhRMA poll shows that initial support for Medicare “negotiation” evaporates once Americans are presented with arguments around the debate. Public opinion dips by as much as 51 points, overall, when Americans see arguments both for and against drug price “negotiations.”

Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) filed a complaint in the U.S. District Court for the Eastern District of Arkansas challenging provisions in Arkansas Act 1103 that seek to require manufacturers to provide federal 340B program pricing to Arkansas-based pharmacies contrary to federal statute.

Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Stephen J. Ubl issued the following statement today on the release of the Biosimilar User Fee Act (III) Performance Goals Letter.

Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Stephen J. Ubl made the following statement in response to the administration’s drug pricing plan.

Pharmaceutical Research and Manufacturers of America president and CEO Stephen J. Ubl made the following statement after the nonpartisan Congressional Budget Office (CBO) released a new report that found policies like those included in Speaker Nancy Pelosi’s drug pricing plan (H.R. 3) will lead to 60 fewer new treatments in the next three decades.

For nearly 30 years, the Prescription Drug User Fee Act (PDUFA) has helped the U.S. Food and Drug Administration (FDA) fulfill its central mission to help protect and advance the public health by allowing the Agency to keep pace with the number and complexity of innovative drugs and biologics entering the regulatory review pipeline.